MedTrace Logo

Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation

NCT03265964 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-08-15

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for suicidal ideation in veterans.

The investigators hypothesize that the administration of a naturally occurring dietary supplement, uridine, will rapidly reduce suicidal ideation in veterans. The purpose of this study is to determine whether 4 weeks of uridine supplementation is an effective treatment for suicidal ideation in veterans, when compared to a group taking a placebo.

Conditions

Interventions

DRUG

Uridine

Uridine is the active treatment in this clinical trial.

DRUG

Placebo

Pill placebo is the inactive treatment comparator in this clinical trial.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Douglas Gavin Kondo, MD · VA Salt Lake City Health Care System, Salt Lake City, UT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2024-06-30
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03265964 on ClinicalTrials.gov